



- The applicant submitted the responses to the CHMP list of outstanding issues on 3 February 2006.
- During the meeting on 21-23 February 2006, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a Marketing Authorisation to M-M-RVAXPRO on 23 February 2006. The applicant provided the letter of undertaking on the follow-up measures to be fulfilled post-authorisation on 23 February 2006
- The CHMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decisions on 5 May 2006.